Latest News about SNY
Recent news which mentions SNY
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
From Benzinga
From Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
February 16, 2022
From InvestorPlace
3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch
February 16, 2022
From Motley Fool
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
February 10, 2022
From Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
Could This New Indication Create a Blockbuster for Pfizer?
February 05, 2022
From Motley Fool
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
From Benzinga
From Benzinga
Earnings Scheduled For February 4, 2022
February 04, 2022
From Benzinga
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
February 02, 2022
From Benzinga
Is AbbVie Stock a Buy Now?
February 01, 2022
From Motley Fool
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
From Benzinga
5 Things To Expect This Week
January 31, 2022
From InvestorPlace
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
From Benzinga
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
January 31, 2022
From Benzinga
Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?
January 29, 2022
From Motley Fool
From Benzinga
From Benzinga
Why Jim Cramer Like NextEra Energy And Lincoln Electric?
January 21, 2022
From Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
January 19, 2022
From Benzinga
3 Under-the-Radar COVID Stocks
January 19, 2022
From Motley Fool
From MarketWatch
3 Top Biotech Stocks to Buy Right Now
January 15, 2022
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.